67 results on '"Balzano, G"'
Search Results
2. Evaluation of Treatment Appropriateness in Patients Submitted to Surgery for Non-functioning Pancreatic Neuroendocrine Tumors (NF-PanNETs)
3. Redefining Prognostic Factors in Potentially Upfront Resectable Pancreatic Head Cancer after Neoadjuvant Chemotherapy
4. Diagnostic Work-up and Surgical Management of Insulinoma - A Retrospective Analysis From a Tertiary Referral Center
5. OC.03.7 ENDOSCOPIC ULTRASOUND-GUIDED ABLATION WITH HYBRIDTHERM PROBE IN ADDITION TO CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR THE TREATMENT OF LOCALLY ADVANCED OR BORDERLINE RESECTABLE PANCREATIC CANCER: A PHASE II RANDOMIZED CONTROLLED TRIAL
6. AF.109 DIAGNOSTIC WORK-UP AND SURGICAL MANAGEMENT OF INSULINOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF 77 CASES
7. PO-1225 Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer
8. Resectability is in the eye of the observer. A multicentre, blinded, prospective assessment of NCCN resectability status classification for pancreatic cancer
9. EUS-ablation with hybridtherm probe plus chemotherapy versus chemotherapy alone in locally advanced/borderline resectable pancreatic cancer: A phase II randomized controlled trial
10. Diagnostic work-up and surgical management of insulinoma: A single-center retrospective analysis of 77 cases
11. Postoperative outcomes and functional recovery after neoadjuvant chemotherapy for pancreatic cancer: A propensity score-matched study
12. Prognostic role of resection margins after pancreatectomy for adenocarcinoma of the head of the pancreas
13. Implications of Increased Serum Amylase after Pancreaticoduodenectomy: Toward a Better Definition of Clinically Relevant Postoperative Acute Pancreatitis
14. The impact of minimally invasive surgery on hospital readmissions and functional recovery after distal pancreatectomy.
15. Impact of adherence to enhanced recovery pathway interventions on recovery following distal-pancreatectomy.
16. Positive neck margin at frozen section analysis is a significant preditor of tumour recurrence and poor survival after pancreatoduodenectomy for pancreatic cancer
17. Site and size of MPD dilation in determining malignant degeneration of IPMNs.
18. Tumor size but not margin status is an indipendent prognostic factor for body/tail ductal adenocarcinoma after distal pancreatectomy
19. Vascular resections during pancreatectomy for pancreatic cancer: a technical issue or a prognostic sign?
20. T03.01.8 LONG-TERM PANCREATIC FUNCTIONAL IMPAIRMENT AFTER SURGERY FOR NEUROENDOCRINE NEOPLASMS
21. OC.09.5 SIZE AND SITE OF MAIN PANCREATIC DUCT DILATION CORRELATES WITH DISTINCT RISK OF MALIGNANCY IN MAIN-DUCT/ MIXED INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS OF THE PANCREAS
22. Time to CA19.9 nadir: a clue for defining treatment duration of primary chemotherapy in resectable PDAC
23. Minimally invasive versus open distal pancreatectomy for ductal adenocarcinoma (DIPLOMA): a pan-European propensity score matched study
24. A randomized phase II trial on neoadjuvant chemotherapy in resectable pancreatic adenocarcinoma
25. P.04.13 NEEDLE TRACT SEEDING OF PANCREATIC CANCER AFTER EUS-FNA: SYSTEMATIC REVIEW OF THE LITERATURE, DISCUSSION OF ITS MANAGEMENT AND REPORT OF A CASE
26. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma
27. Modeling the Iatrogenic Pancreatic Cancer Risk After Islet Autotransplantation in Mouse
28. Randomized phase 2 trial of peri- or post-operative chemotherapy in resectable pancreatic adenocarcinoma
29. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in metastatic pancreatic adenocarcinoma
30. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in metastatic pancreatic adenocarcinoma
31. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?
32. Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma
33. A randomized phase 2 trial of nab-paclitaxel plus gemcitabine, ± capecitabine, cisplatin (paxg regimen) in unresectable or borderline resectable pancreatic adenocarcinoma: the ghost regimen strikes back
34. Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis
35. Long-term safety of islet autotransplantation in patients with malignancy
36. Early postoperative prediction of clinically relevant pancreatic fistula after pancreaticoduodenectomy
37. Downstaging of liver metastases from pancreatic cancer following primary chemotherapy: A new indication for surgery?
38. Delayed post-pancreatectomy hemorrhage after left pancreatectomy: Incidence, risk factors and unusual clinical presentations
39. Assessment of the external validity of a predictive model based on amylase value in drains for fistula risk after pancreaticoduodenectomy
40. Spleen-preserving pancreatic resections with preservation of splenic vessels: A cautionary note on the risk of vascular complications
41. Management and outcome of pancreatic resections performed in high and low volume centers by surgeons sharing the same mentor: The importance of training.
42. Phase Ib Trial of Nab-Paclitaxel Plus Gemcitabine, Capecitabine, and Cisplatin (Paxg Regimen) in Patients with Stage III Pancreatic Adenocarcinoma
43. LBA.02.3 PERIOPERATIVE OUTCOME OF MINIMALLY INVASIVE SPLEEN-PRESERVING DISTAL PANCREATECTOMY: RESULTS OF A MULTICENTER SURVEY IN ITALY
44. A new minimally invasive technique for benign neoplasm of the pancreatic body: Laparoscopic spleen-preserving distal pancreatectomy with autologous islet transplantation (AIT)
45. Enhanced recovery after surgery in pancreatic surgery: Preliminary data on safety and adherence for new pathways
46. Autologous islet transplantation to improve glycaemic control following extended pancreatectomy: indications and outcome
47. Maintenance therapy with alpha-interferon (IFN-α) in locally advanced pancreatic cancer (LAPC): A pilot study
48. Metastatic site in pancreatic adenocarcinoma (PA) correlates with prognosis
49. Short-term outcome and cost-benefit analysis of laparoscopic left pancreatectomy: Results of a case-match study
50. 6599 Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine in pancreatic cancer: a randomized phase II trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.